Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial.
Kodama, Shinichiro, Nakata, Mitsuko, Konishi, Nafuko et al. · Nutrients · 2026 · DOI
Quick Summary
This study tested whether vitamin D supplementation could help people with ME/CFS who developed the condition after COVID-19 vaccination or infection and had low vitamin D levels. Half the participants received vitamin D supplements plus guidance on diet and sun exposure, while the other half received only the supplement. The group that received full guidance had significantly more symptom improvement, with 16 people improving enough to no longer meet ME/CFS diagnostic criteria compared to just 1 person in the other group.
Why It Matters
ME/CFS affecting post-COVID and post-vaccination populations represents a growing clinical burden with limited evidence-based treatments. This study provides the first RCT evidence that targeted vitamin D replacement may significantly improve ME/CFS symptoms in the subset of patients with documented deficiency, potentially offering an accessible, low-risk intervention for a subset of affected individuals.
Observed Findings
Intervention group showed mean symptom reduction of 6.7 symptoms compared to 1.2 in controls (between-group difference -5.6; 95% CI: -7.2, -3.9; p<0.001)
Vitamin D levels improved from 18.6 to 27.1 ng/mL in intervention group versus declining trend in control group (between-group difference 10.2 ng/mL; 95% CI: 7.9, 12.5)
16 participants in intervention group achieved <8 symptoms (no longer meeting ME/CFS diagnostic criteria) compared to 1 control participant (p<0.001)
Benefits were consistent across both post-vaccination syndrome (n=56) and post-acute COVID syndrome (n=29) subgroups
Inferred Conclusions
Vitamin D replacement therapy guidance significantly reduces ME/CFS symptom burden in patients with documented vitamin D insufficiency or deficiency
Comprehensive vitamin D management (supplementation plus dietary counseling, sun exposure guidance, and exercise) produces greater clinical benefit than supplementation alone
Vitamin D repletion may represent a potentially modifiable factor contributing to ME/CFS symptom severity in vulnerable populations
Remaining Questions
What is the mechanism by which vitamin D deficiency contributes to ME/CFS pathophysiology, and does repletion address underlying immunological or metabolic dysfunction?
Could a double-blind, placebo-controlled design more definitively establish vitamin D supplementation's independent contribution versus lifestyle modification benefits?
What This Study Does Not Prove
This study does not establish that vitamin D deficiency causes ME/CFS; it only demonstrates that correcting deficiency in those who already have ME/CFS can improve symptoms. The open-label design introduces potential bias, and the intervention combined multiple elements (supplementation plus lifestyle counseling), so the independent contribution of vitamin D versus diet/exercise cannot be isolated. Results apply only to patients with confirmed vitamin D insufficiency/deficiency and may not generalize to ME/CFS patients with normal vitamin D levels.
Do patients achieve sustained symptom improvement beyond 12 weeks, and what are optimal vitamin D target levels for this population?
What proportion of ME/CFS patients overall have vitamin D deficiency, and would universal screening and repletion be cost-effective as a population-level intervention?